Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion
Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion.
Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement.
This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy